Latest Commercialisation News

Proteomics International has published clinical validation results for PromarkerEso, a novel blood test that detects esophageal adenocarcinoma with remarkable accuracy, promising a non-invasive alternative to costly and uncomfortable endoscopy procedures.

Sparc Technologies has successfully closed its Share Purchase Plan, raising more than double its initial target, signaling strong shareholder confidence as it advances its green hydrogen and graphene projects.

Nimy Resources reports promising signs of a large, continuous gallium mineralised system at its Block 3 Gallium Project in Western Australia, with drilling confirming key host rocks over 1.5 kilometres of strike. Assay results are imminent as the company advances exploration and metallurgical testing.

Proteomics International has completed a $12 million capital raise, including a heavily oversubscribed Share Purchase Plan, to fast-track the rollout of its innovative diagnostic tests in Australia and the USA.

Wide Open Agriculture Ltd has announced a Share Purchase Plan aiming to raise up to $500,000 through the issue of new shares and free-attaching options, pending shareholder approval. This capital raise complements a recent $2.6 million placement to support the company’s growth and production ramp-up.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

New Frontier Minerals Ltd highlights significant exploration progress at its Harts Range heavy rare earths project and the NWQ Copper Project, backed by strategic partnerships and promising assay results.

Pursuit Minerals has dispatched high-purity lithium carbonate samples from its Argentine pilot plant to potential partners, advancing feasibility studies for a 5,000tpa operation while exploring strategic acquisitions in precious and base metals.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

Volt Resources has reshaped its executive team to sharpen focus on downstream graphite refining and advanced materials, appointing Trevor Matthews to its board while repositioning CEO Prashant Chintawar.